Cargando…

The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients

BACKGROUND: The monocyte-to-lymphocyte ratio (MLR) is considered as a new inflammation marker. This study was aimed to investigate the prognostic value of MLR for all-cause mortality and new-onset cardiovascular disease (CVD) events in peritoneal dialysis (PD) patients. METHODS: This study enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yan, Xu, Yuanyuan, Lu, Peiyu, Zhou, Hua, Yang, Min, Xiang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084613/
https://www.ncbi.nlm.nih.gov/pubmed/37038225
http://dx.doi.org/10.1186/s40001-023-01073-y
_version_ 1785021775470395392
author Yang, Yan
Xu, Yuanyuan
Lu, Peiyu
Zhou, Hua
Yang, Min
Xiang, Li
author_facet Yang, Yan
Xu, Yuanyuan
Lu, Peiyu
Zhou, Hua
Yang, Min
Xiang, Li
author_sort Yang, Yan
collection PubMed
description BACKGROUND: The monocyte-to-lymphocyte ratio (MLR) is considered as a new inflammation marker. This study was aimed to investigate the prognostic value of MLR for all-cause mortality and new-onset cardiovascular disease (CVD) events in peritoneal dialysis (PD) patients. METHODS: This study enrolled patients receiving PD treatment for  ≥ 3 months. Baseline characteristics were obtained within 1 week before PD catheterization. The receiver operating characteristic curve analysis was conducted to determine the optimal cut-off value of MLR. The Kaplan–Meier curve estimated the cumulative survival rate and new CVD free survival rate. Univariate and multivariate Cox regression models were preformed to investigate the association between MLR and clinical outcomes. RESULTS: A total of 369 PD patients participated in this study. During a median follow-up period of 32.83 months, 65 patients (24.2%) died, and 141 patients (52.4%) occurred new-onset CVD events. The Kaplan–Meier curve revealed that survival rate in high MLR group (MLR  > 0.2168) was significantly lower than in low MLR group (P = 0.008). Patients in high MLR group were more likely to experience CVD events (P = 0.002). Even after adjustment of traditional risk factors, including age, diabetes mellitus, CVD history, smoking, hyperlipidemia, high MLR remained an independent predictor of all-cause mortality [hazard ration (HR) = 2.518, 95% confidence intervals (CI) = 1.020–6.214, P = 0.045] and new-onset CVD events (HR = 1.815, 95% CI = 1.157–2.849, P = 0.010). CONCLUSIONS: This study suggested that high MLR was significantly and independently associated with all-cause mortality and CVD events in PD patients. The MLR is an inexpensive and straightforward indicator to reflect systemic inflammation status and help clinicians improve PD management. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01073-y.
format Online
Article
Text
id pubmed-10084613
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100846132023-04-11 The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients Yang, Yan Xu, Yuanyuan Lu, Peiyu Zhou, Hua Yang, Min Xiang, Li Eur J Med Res Research BACKGROUND: The monocyte-to-lymphocyte ratio (MLR) is considered as a new inflammation marker. This study was aimed to investigate the prognostic value of MLR for all-cause mortality and new-onset cardiovascular disease (CVD) events in peritoneal dialysis (PD) patients. METHODS: This study enrolled patients receiving PD treatment for  ≥ 3 months. Baseline characteristics were obtained within 1 week before PD catheterization. The receiver operating characteristic curve analysis was conducted to determine the optimal cut-off value of MLR. The Kaplan–Meier curve estimated the cumulative survival rate and new CVD free survival rate. Univariate and multivariate Cox regression models were preformed to investigate the association between MLR and clinical outcomes. RESULTS: A total of 369 PD patients participated in this study. During a median follow-up period of 32.83 months, 65 patients (24.2%) died, and 141 patients (52.4%) occurred new-onset CVD events. The Kaplan–Meier curve revealed that survival rate in high MLR group (MLR  > 0.2168) was significantly lower than in low MLR group (P = 0.008). Patients in high MLR group were more likely to experience CVD events (P = 0.002). Even after adjustment of traditional risk factors, including age, diabetes mellitus, CVD history, smoking, hyperlipidemia, high MLR remained an independent predictor of all-cause mortality [hazard ration (HR) = 2.518, 95% confidence intervals (CI) = 1.020–6.214, P = 0.045] and new-onset CVD events (HR = 1.815, 95% CI = 1.157–2.849, P = 0.010). CONCLUSIONS: This study suggested that high MLR was significantly and independently associated with all-cause mortality and CVD events in PD patients. The MLR is an inexpensive and straightforward indicator to reflect systemic inflammation status and help clinicians improve PD management. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01073-y. BioMed Central 2023-04-10 /pmc/articles/PMC10084613/ /pubmed/37038225 http://dx.doi.org/10.1186/s40001-023-01073-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Yan
Xu, Yuanyuan
Lu, Peiyu
Zhou, Hua
Yang, Min
Xiang, Li
The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients
title The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients
title_full The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients
title_fullStr The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients
title_full_unstemmed The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients
title_short The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients
title_sort prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084613/
https://www.ncbi.nlm.nih.gov/pubmed/37038225
http://dx.doi.org/10.1186/s40001-023-01073-y
work_keys_str_mv AT yangyan theprognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT xuyuanyuan theprognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT lupeiyu theprognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT zhouhua theprognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT yangmin theprognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT xiangli theprognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT yangyan prognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT xuyuanyuan prognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT lupeiyu prognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT zhouhua prognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT yangmin prognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients
AT xiangli prognosticvalueofmonocytetolymphocyteratioinperitonealdialysispatients